NEW YORK (GenomeWeb) – Curetis reported today a 9 percent decline in revenues for the first half of 2017, reflecting market volatility for its Unyvero molecular diagnostic system.

For the six-month period ended June 30, Curetis' revenues fell to €594,800 ($695,176) from €654,682 in the first half of 2016. The firm said that due to the uneven spread of early-stage instrument sales throughout the year, revenue volatility is expected quarter to quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.